H-CYTE, Inc. (HCYT)
Stock Price:
$0.0700 USD
0.0026 (3.86%)
Updated Aug 5, 2020 4:00 PM EDT - End of day
Key Info
| Market Cap |
7.30M |
| Revenue (ttm) |
8.04M |
| Net Income (ttm) |
-28.53M |
| Shares Out |
104.25M |
| EPS (ttm) |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 5, 2020 |
| Last Price |
$0.0700 |
| Previous Close |
$0.0674 |
| Change ($) |
0.0026 |
| Change (%) |
3.86% |
| Day's Open |
0.0490 |
| Day's Range |
0.0490 - 0.0673 |
| Day's Volume |
5,976 |
| 52-Week Range |
0.0300 - 0.3500 |
More Stats
| Market Cap |
7.30M |
| Enterprise Value |
10.02M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
104.25M |
| Float |
37.22M |
| EPS (basic) |
n/a |
| EPS (diluted) |
n/a |
| FCF / Share |
-0.10 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
253,311 |
| Short Ratio |
5.33 |
| Short % of Float |
1.40% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
0.91 |
| PB Ratio |
1.90 |
| Revenue |
8.04M |
| Operating Income |
-29.69M |
| Net Income |
-28.53M |
| Free Cash Flow |
-10.03M |
| Net Cash |
-2.73M |
| Net Cash / Share |
-0.03 |
| Gross Margin |
78.29% |
| Operating Margin |
-369.27% |
| Profit Margin |
-393.50% |
| FCF Margin |
-124.73% |
| ROA |
-107.79% |
| ROE |
-1,647.08% |
| ROIC |
1,364.20% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
1.75
Current: $0.0700
High
1.75
Target: 1.75
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|
| Revenue | 8.35 | 7.88 | 0.21 | - | - | - |
| Revenue Growth | 5.88% | 3701.95% | - | - | - | - |
| Gross Profit | 6.29 | 5.52 | 0.04 | - | - | - |
| Operating Income | -30.56 | -4.19 | -6.06 | -12.86 | -5.54 | -2.94 |
| Net Income | -29.81 | -4.39 | - | -16.23 | -6.52 | -2.94 |
| Shares Outstanding | 96.37 | 33.66 | 19.14 | 13.25 | 10.94 | 7.90 |
| Earnings Per Share | -0.34 | -0.13 | -0.34 | -1.22 | -0.60 | -0.37 |
| Operating Cash Flow | -12.29 | -3.54 | -5.59 | -5.43 | -5.98 | -2.76 |
| Capital Expenditures | -0.02 | -0.01 | -0.02 | -0.09 | -0.01 | -0.02 |
| Free Cash Flow | -12.31 | -3.56 | -5.61 | -5.51 | -5.99 | -2.78 |
| Cash & Equivalents | 1.42 | 0.07 | 0.25 | 0.90 | 1.57 | 6.68 |
| Total Debt | 2.44 | 4.49 | 0.17 | 1.20 | 1.05 | - |
| Net Cash / Debt | -1.02 | -4.42 | 0.08 | -0.30 | 0.52 | 6.68 |
| Assets | 3.27 | 0.45 | 1.23 | 1.51 | 11.53 | 6.87 |
| Liabilities | 6.67 | 6.52 | 0.51 | 1.96 | 1.51 | 0.36 |
| Book Value | -9.09 | -5.70 | 0.71 | -0.45 | 10.02 | 6.51 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
H-CYTE, Inc. |
| Country |
United States |
| CEO |
William E. Horne |
Stock Information
| Ticker Symbol |
HCYT |
| Stock Exchange |
US OTC |
| Sector |
Healthcare |
| Industry |
Medical Devices |
| Unique Identifier |
OTCMKTS: HCYT |
Description
H-CYTE, Inc., a medical biosciences company, develops and implements various treatment options in regenerative medicine to treat chronic lung diseases. It engages in the development of L-CYTE-01 for the treatment of chronic obstructive pulmonary diseases. The company is headquartered in Tampa, Florida.